stoxline Quote Chart Rank Option Currency Glossary
Catalyst Pharmaceuticals, Inc. (CPRX)
16.475  0.165 (1.01%)    07-12 13:45
Open: 16.5
High: 16.91
Volume: 293,982
Pre. Close: 16.31
Low: 16.42
Market Cap: 1,946(M)
Technical analysis
2024-07-12 1:19:52 PM
Short term     
Mid term     
Targets 6-month :  19.75 1-year :  23.06
Resists First :  16.9 Second :  19.75
Pivot price 15.53
Supports First :  15.57 Second :  14.75
MAs MA(5) :  15.85 MA(20) :  15.43
MA(100) :  15.62 MA(250) :  14.52
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  76.2 D(3) :  70.7
RSI RSI(14): 62.4
52-week High :  17.5 Low :  11.55
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CPRX ] has closed Bollinger Bands are 15.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.44 - 16.52 16.52 - 16.59
Low: 15.44 - 15.53 15.53 - 15.61
Close: 16.16 - 16.3 16.3 - 16.44
Company Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Headline News

Fri, 12 Jul 2024
Daiwa Securities Group Inc. Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

Thu, 11 Jul 2024
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Thu, 11 Jul 2024
GSA Capital Partners LLP Purchases Shares of 59,838 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Wed, 10 Jul 2024
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Wed, 10 Jul 2024
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Wed, 10 Jul 2024
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 118 (M)
Shares Float 102 (M)
Held by Insiders 6.2 (%)
Held by Institutions 83.2 (%)
Shares Short 6,810 (K)
Shares Short P.Month 7,990 (K)
Stock Financials
EPS 0.56
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.76
Profit Margin 15.8 %
Operating Margin 27.5 %
Return on Assets (ttm) 9.2 %
Return on Equity (ttm) 14.5 %
Qtrly Rev. Growth 15.3 %
Gross Profit (p.s.) 0
Sales Per Share 3.48
EBITDA (p.s.) 0.96
Qtrly Earnings Growth -26.9 %
Operating Cash Flow 163 (M)
Levered Free Cash Flow -34 (M)
Stock Valuations
PE Ratio 29.33
PEG Ratio 0
Price to Book value 3.45
Price to Sales 4.71
Price to Cash Flow 11.87
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android